论文部分内容阅读
目的探讨HER-2浓度与组织表达的一致性,以及对乳腺癌预后的临床意义。方法 2012年3月至2013年3月期间,本院诊治的80例复发转移乳腺癌患者,通过ELISA法和免疫组化法,分别检测血清HER-2蛋白浓度和HER-2表达水平,对两者检测结果进行统计分析。结果 33例组织HER-2阳性复发转移乳腺癌患者中,25例血清HER-2阳性,其阳性符合率为75.8%;47例组织HER-2阴性复发转移乳腺癌患者中,39例血清HER-2阴性,其阴性符合率为83.0%。血清HER-2浓度与组织HER-2表达水平呈正相关性,两者检测结果具有一致性。结论血清HER-2浓度与组织HER-2表达水平评估乳腺癌的检测结果具有一致性,能够作为患者预后参考指标。
Objective To investigate the consistency between HER-2 concentration and tissue expression and the clinical significance of prognosis in breast cancer. Methods From March 2012 to March 2013, 80 patients with recurrent breast cancer who were diagnosed and treated in our hospital were enrolled in this study. Serum HER-2 protein and HER-2 expression levels were detected by ELISA and immunohistochemistry. Who test results for statistical analysis. Results Among the 33 cases with HER-2 positive breast cancer, 25 cases were positive for HER-2, and the positive coincidence rate was 75.8%. Among the 47 cases with HER-2 negative recurrence and metastasis, 39 cases of HER- 2 negative, the negative coincidence rate was 83.0%. The concentration of HER-2 in serum was positively correlated with the expression of HER-2 in the tissue, and the results of the two tests were consistent. Conclusion Serum HER-2 levels and tissue HER-2 expression levels in the assessment of breast cancer test results are consistent and can be used as a prognostic reference for patients.